Objective: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.; Background: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase.; Method: Participants […]